Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/218975Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Cantarero, David | - |
| dc.contributor.author | Ocaña, Daniel | - |
| dc.contributor.author | Onieva-García, María Ángeles | - |
| dc.contributor.author | Rodríguez-García, Juan | - |
| dc.contributor.author | Gálvez, Paulina | - |
| dc.contributor.author | Méndez, Cristina | - |
| dc.contributor.author | Crespo Palomo, Carlos | - |
| dc.contributor.author | López-Ibáñez de Aldecoa, Alejandra | - |
| dc.date.accessioned | 2025-02-19T12:34:37Z | - |
| dc.date.available | 2025-02-19T12:34:37Z | - |
| dc.date.issued | 2023-08-14 | - |
| dc.identifier.issn | 0264-410X | - |
| dc.identifier.uri | https://hdl.handle.net/2445/218975 | - |
| dc.description.abstract | A cost-utility analysis was conducted to assess the efficiency of implementing a PCV20 vaccination strategy in the Spanish adult population older than 60 years, for the prevention of non-bacteremic pneumococcal pneumonia (NBP) and invasive pneumococcal disease (IPD). | - |
| dc.format.extent | 8 p. | - |
| dc.format.mimetype | application/pdf | - |
| dc.language.iso | eng | - |
| dc.publisher | Elsevier B.V. | - |
| dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.vaccine.2023.07.016 | - |
| dc.relation.ispartof | Vaccine, 2023, vol. 41, num.36, p. 5342-5349 | - |
| dc.relation.uri | https://doi.org/10.1016/j.vaccine.2023.07.016 | - |
| dc.rights | cc-by-nc-nd (c) Elsevier B.V., 2023 | - |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
| dc.source | Articles publicats en revistes (Genètica, Microbiologia i Estadística) | - |
| dc.subject.classification | Vacuna antipneumocòccica | - |
| dc.subject.classification | Anàlisi cost-benefici | - |
| dc.subject.other | Pneumococcal vaccine | - |
| dc.subject.other | Cost effectiveness | - |
| dc.title | Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain | - |
| dc.type | info:eu-repo/semantics/article | - |
| dc.type | info:eu-repo/semantics/acceptedVersion | - |
| dc.identifier.idgrec | 738565 | - |
| dc.date.updated | 2025-02-19T12:34:37Z | - |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
| Appears in Collections: | Articles publicats en revistes (Genètica, Microbiologia i Estadística) | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 826090.pdf | 753.46 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License
